Q1 FY2022 (April 1 to June 30, 2022) Conference Call

Sumitomo Pharma Co., Ltd.

Sumitomo Pharma
Innovation today, healthier tomorrows

July 29, 2022

Disclaimer Regarding Forward-looking Statements

This material contains forecasts, projections, goals, plans, and other forward-looking statements regarding the Group's financial results and other data. Such forward-looking statements are based on the Company's assumptions, estimates, outlook, and other judgments made in light of information available at the time of preparation of such statements and involve both known and unknown risks and uncertainties.

Accordingly, forecasts, plans, goals, and other statements may not be realized as described, and actual financial results, success/failure or progress of development, and other projections may differ materially from those presented herein.

Information concerning pharmaceuticals and medical devices (including compounds under development) contained herein is not intended as advertising or as medical advice.

Myovant Sciences Ltd. ("Myovant") is listed on the New York Stock Exchange, and the Group holds approximately 52% of the outstanding shares of Myovant. ORGOVYX® (relugolix), MYFEMBREE®/RYEQO® (relugolix combination tablet) are owned by Myovant. This material contains information about Myovant, which is based on information disclosed by Myovant. For more information on Myovant, please visit https://www.myovant.com.

Financial Results for Q1 FY2022

Financial Results for Q1 FY2022 (Core Basis)

Billions of yen

	Q1YTD FY2021 Results	Q1YTD FY2022 Results	Change			FY2022	
			Value	FX impact	%	May 13 forecasts	%
Revenue	131.2	**159.9**	28.7	16.4	21.9	550.0	29.1
Cost of sales	38.5	**46.1**	7.6	4.0	19.7	164.5	28.0
Gross profit	92.7	**113.8**	21.1	12.4	22.8	385.5	29.5
SG&A expenses	62.0	**76.0**	14.1	9.2	22.7	283.5	26.8
R&D expenses	22.4	**24.4**	2.0	2.9	8.9	93.0	26.3
Other operating income/expenses	0.2	**0.0**	(0.2)	–	–	21.0	–
Core operating profit	8.5	**13.4**	4.9	0.3	57.2	30.0	44.6
Changes in fair value of contingent consideration (negative number indicates loss)	(0.1)	**(0.1)**	0.0			(0.5)	
Other non-recurring items (negative number indicates loss)	(0.1)	**1.3**	1.4			(5.5)	
Operating profit	8.3	**14.6**	6.3		75.9	24.0	60.9
Finance income/costs	(0.3)	**32.0**	32.3				
Profit before taxes	8.0	**46.6**	38.7		485.8		
Income tax expenses	7.2	**18.5**	11.4				
Net profit	0.8	**28.1**	27.3		–		
Net profit attributable to owners of the parent	4.8	**31.1**	26.3		547.8	22.0	141.4

The forecasts are not revised

(Ref.) Earnings related to Sumitovant

Billions of yen

	Q1 FY21	Q1 FY22
Revenue	**5.8**	**20.7**
SG&A expenses *	19.9	29.8
R&D expenses	5.9	7.1
Core operating profit	**(20.7)**	**(20.8)**
Operating profit	**(20.7)**	**(20.8)**
Net profit	(21.0)	(23.8)
Net profit attributable to owners of the parent	**(17.0)**	**(20.7)**

The figures include intra-group transaction

* Include amortization of patent rights

Average rates:
Q1FY2021 Results : 1US$ = ¥109.5, 1RMB = ¥17.0
Q1FY2022 Results : 1US$ = ¥129.7, 1RMB = ¥19.6
FY2022 forecasts : 1US$ = ¥125.0, 1RMB = ¥19.5

Period end rates:
As of the end of March 2022 : 1US$ = ¥122.4, 1RMB = ¥19.3
As of the end of June 2022 : 1US$ = ¥136.6, 1RMB = ¥20.4

Sumitomo Pharma

Revenue of Major Products in Japan

Billions of yen

	Q1 YTD FY2021 Results	Q1 YTD FY2022 Results	Change		FY2022	
			Value	%	May 13 forecasts	%
Equa®/EquMet®	9.8	**8.8**	△1.0	△10.4	34.9	25.2
Trulicity® *	8.8	**8.6**	△0.2	△2.2	31.0	27.8
TRERIEF®	4.3	**4.4**	0.1	2.7	17.3	25.6
LATUDA®	1.4	**2.3**	0.9	65.5	9.9	23.2
METGLUCO®	2.1	**2.0**	△0.1	△5.2	7.8	25.5
LONASEN® Tape	0.5	**0.7**	0.2	41.6	2.7	24.4
TWYMEEG®	–	**0.1**	0.1	–	1.5	6.9
AG products	2.4	**2.3**	△0.1	△4.4	9.7	23.9
Others	9.3	**4.5**	△4.9	△52.1	15.2	29.4
合計	38.7	**33.7**	△5.0	△12.9	130.0	25.9

Note: Sales of each product are shown by invoice price (* Trulicity® is shown by NHI price)

- Progress is almost as forecasted in the segment total
- LATUDA® showing steady growth
- Prescription days limit of TWYMEEG® will be lifted in September 2022
- Sale of REPREGAL® included “Others” decreased (Q1 YTD FY2021: ¥3.5B)
- NHI price revision affected (¥3.2B) on Japan segment total

Revenue of Major Products in North America & China

	Q1 YTD FY2021 Resuts	Q1 YTD FY2022 Results	Change	Q1 YTD FY2021 Resuts	Q1 YTD FY2022 Results	Change			FY2022		
						Value	FX impact	%	May 13 forecasts		Yen-basis %
North America	Million $			Billions of yen					Million $	Billions of yen	
LATUDA®	469	482	13	51.4	62.5	11.1	9.7	21.7	1,726	215.8	29.0
APTIOM®	63	65	2	6.9	8.4	1.5	1.3	21.3	255	31.8	26.4
RETHYMIC®	—	5	5	—	0.7	0.7	0.1	—	48	6.0	11.8
BROVANA®	51	14	△37	5.6	1.8	△3.8	0.3	△68.6	26	3.2	54.7
KYNMOBI®	2	△0	△2	0.2	△0.0	△0.3	△0.0	△110.9	18	2.3	△1.1
ORGOVYX®	11	36	25	1.2	4.7	3.5	0.7	293.5	601	75.2	29.0
MYFEMBREE®	1	4	3	0.1	0.5	0.4	0.1	339.8			
GEMTESA®	7	34	27	0.8	4.4	3.6	0.7	454.4			
Others	48	94	47	5.2	12.2	7.0	1.9	135.2			
Total	652	733	82	71.4	95.2	23.8	14.8	33.3	2,674	334.3	28.5
China	Million RMB			Billions of yen					Million RMB	Billions of yen	
MEROPEN®	392	464	72	6.6	9.1	2.5	1.2	37.7	863	16.8	54.1
Others	111	129	19	1.9	2.5	0.6	0.3	31.9	553	10.8	23.5
Total	503	594	91	8.5	11.6	3.1	1.6	36.4	1,416	27.6	42.1

- **North America segment**
  Revenue increased due to the impact of fluctuations in FX rates and products of Sumitovant
- Sale of LATUDA® is in line with forecasts
- BROVANA® decreased due to loss of exclusivity in June 2021
- Revenue of $50M from the license agreement for ORGOVYX® in EU is recorded in “Others”
- **China segment**
  MEROPEN® increased continuously

FX rates:
Q1FY2021 Results : 1US$ = ¥109.5, 1RMB = ¥17.0
Q1FY2022 Results : 1US$ = ¥129.7, 1RMB = ¥19.6
FY2022 forecasts : 1US$ = ¥125.0, 1RMB = ¥19.5

Sumitomo Pharma

Marketing Status of ORGOVYX®

- Obtained approx. 3,500 new patient starts in Q1 FY2022 (24% growth vs. Q4 FY2021)



Estimated Cumulative Patients Treated with ORGOVYX®

(includes patients on free and commercial drug, excludes patients utilizing product samples)

- Prescribed approx. 18,000 patients since launch
- Prescribed approx. 80% of the total at Dispensing Clinics, Academic, etc.
- Secured broad payer coverage continues
  - Commercial – 81% of lives
  - Medicare Part D – 99% of lives

- 75% of patients pay less than $60 out of pocket per month
- Gross to Net remains in the low-to-mid 40% range

Source：Presentation of First Fiscal Quarter 2022 Earnings Conference Call of Myovant Sciences Ltd.

Marketing Status of MYFEMBREE®

- Obtained approx. 2,400 new patient starts in Q1 FY2022 (71% growth vs. Q4 FY2021)



Estimated Cumulative Patients Treated with MYFEMBREE®
(includes patients on free and commercial drug, excludes patients utilizing product samples)

- Prescribed approx. 5,800 patients since launch
- Achieved 2.8 times class growth in TRx for GnRH antagonists therapies for uterine fibroids since MYFEMBREE® launch
- Secured broad payer coverage continues
  Commercial – 94% of lives

- Obtained 51% total prescriptions (TRx) share and 57% new-to-brand prescription (NBRx) share among GnRH antagonists therapies for uterine fibroids in June 2022
- 75% of patients pay $5 or less out of pocket per month

Source：Presentation of First Fiscal Quarter 2022 Earnings Conference Call of Myovant Sciences Ltd.

Marketing Status of GEMTESA®

- Prescribed 38,100 TRx in June 2022 and ahead of our FY2022 forecast

	GEMTESA®	
	March 2022	June 2022
TRx Share in Beta 3	6.4%	9.3%
Monthly TRx numbers	26,145	38,100

- Coverage has not expanded since March 2022. Plan to secure most of peak coverage during FY2022

	GEMTESA®	
	March 2022	June 2022
All of commercial lives（Approx. 180 million）	55%	55%
All of Medicare Part D lives（Approx. 48 million）	30%	30%

- Entered into an exclusive license agreement with Pierre Fabre to commercialize vibegron in Europe (July 2022)

  Urovant to receive compensation of up to USD $75 million including upfront payment, regulatory and sales milestones as well as royalties

Financial Results for Q1 FY2022

Segment Information (Core Basis)

Billions of yen

		Pharmaceuticals Business					Other Business	Total
		Japan	North America	China	Other Regions	Subtotal		
Q1 YTD FY2022 Results	Revenue (Sales to customers)	33.7	95.2	11.6	8.4	148.9	11.0	159.9
	Cost of sales	19.1	13.5	3.7	1.2	37.5	8.5	46.1
	Gross profit	14.6	81.7	7.9	7.2	111.4	2.5	113.8
	SG&A expenses	13.0	58.6	2.6	0.4	74.6	1.4	76.0
	Core segment profit	1.6	23.1	5.3	6.8	36.8	1.0	37.8
	R&D expenses					23.8	0.6	24.4
	Core operating profit					13.0	0.4	13.4
Q1 YTD FY2021 Results	Revenue (Sales to customers)	38.7	71.4	8.5	2.7	121.3	9.9	131.2
	Cost of sales	20.0	8.0	1.6	1.3	30.9	7.6	38.5
	Gross profit	18.7	63.4	6.9	1.4	90.5	2.3	92.7
	SG&A expenses	11.9	45.3	2.7	0.8	60.7	1.3	62.0
	Core segment profit	6.7	18.1	4.3	0.6	29.8	1.0	30.8
	R&D expenses					22.3	0.2	22.4
	Core operating profit					7.7	0.9	8.5
Change	Revenue (Sales to customers)	(5.0)	23.8	3.1	5.6	27.5	1.1	28.7
	SG&A expenses	1.1	13.3	(0.1)	(0.4)	13.9	0.2	14.1
	Core segment profit	(5.2)	4.9	1.1	6.2	7.0	0.0	7.0
	R&D expenses					1.5	0.5	2.0
	Core operating profit					5.3	(0.4)	4.9

- **Japan:** Lower profit due to declined sales by NHI price revision and increased expenses
- **North America:** Profit increased since the impact of higher revenue exceeded increased expenses
- **China:** Profit increased mainly due to higher revenue
- **Other Regions:** Profit includes the revenue of $50M from the license agreement for DSP-0187

Research and Development

Research and Development

Development Pipeline (as of July 29, 2022)

: Psychiatry & Neurology : Oncology : Regenerative medicine / Cell therapy : Others : Frontier business

No revisions since the announcement of May 2022

Area	Phase 1		Phase 2	Phase 3	NDA submitted
Japan	**DSP-9632P** (Levodopa-induced dyskinesia in Parkinson's disease) **DSP-0187** (Narcolepsy)	**DSP-0390** (Solid tumors) **TP-3654** (Hematologic malignancies) **DSP-5336** (Hematologic malignancies) **guretolimod (DSP-0509)** (Solid tumors)	**EPI-589** (ALS/Investigator-initiated study) **Allo iPS cell-derived products** (Parkinson's disease/ Investigator-initiated study)	**ulotaront (SEP-363856)** (Schizophrenia) **SEP-4199** (Bipolar I depression)	**METGLUCO® (metformin)** (New indication: infertility treatment)
U.S.	**DSP-6745** (Parkinson's disease psychosis) **SEP-378608** (Bipolar disorder) **DSP-3905** (Neuropathic pain) **SEP-378614** (To be determined) **SEP-380135** (To be determined) **DSP-0038** (Alzheimer's disease psychosis) **DSP-3456 (Treatment resistant depression)**	**guretolimod (DSP-0509)** (Solid tumors) **TP-1287** (Solid tumors) **TP-3654** (Hematologic malignancies) **TP-1454** (Solid tumors) **DSP-0390** (Solid tumors) **DSP-5336** (Hematologic malignancies) **KSP-1007** (Complicated urinary tract infections, Complicated intra-abdominal infections)	**EPI-589** (Parkinson's disease/ALS) **ulotaront (SEP-363856)** (Parkinson's disease psychosis) **dubermatinib (TP-0903)** (AML/Research group-initiated study) **DSP-7888** (Solid tumors) **rodatristat ethyl** (Pulmonary arterial hypertension) **URO-902** (Overactive bladder)	**ulotaront (SEP-363856)** (Schizophrenia) **SEP-4199** (Bipolar I depression) **GEMTESA® (vibegron)** (New indication: OAB in men with BPH)	**MYFEMBREE® (relugolix)** (New indication: Endometriosis) PDUFA goal date: Aug. 2022
China				**LATUDA®** (New indication: Bipolar I depression) **ulotaront (SEP-363856)** (Schizophrenia)	**lefamulin** (Bacterial community-acquired pneumonia)

Sumitomo Pharma

Product Launch Target (Frontier business) (as of July 29, 2022)

Revisions since the announcement of May 2022 are shown in red

: Medical device

: Non-medical device

FY2022	FY2023	FY2024	FY2025	FY2026	FY2027 onward
	Wearable EEG meter (Certification)				
MELTz Hand Rehabilitation System (Certification) *1	Automated blood collection/ Stabilization device		Violet Light (Depression)		Digital medical device for depression diagnosis
Digital device for relieving BPSD*2	Smart device for hard of hearing people	Violet Light (Depression)	Violet Light (Dementia)		Digital device for relieving BPSD (Approval)
VR contents for mental health *3	Wearable EEG meter	Violet Light (Dementia)	MELTz Hand Rehabilitation System (Approval)	VR contents for Social Anxiety Disorder	VR business (Disease area expansion)

*1 Certified medical device named “Active extension / flexion / extension rotation exercise device” (Accepted name for medical devices), plan to launch in August 2022 by Sumitomo Pharma

*2 Full-scale sales primarily by partners (Aikomi : our associated company)

*3 Sales primarily by partners (BehaVR) (Profit share 50-50 with both companies)

The project description varies with the product (device sales, solution business, royalties, etc.)

Appendix

＜Contents＞

Financial Results for Q1 FY2022 (Full Basis)

Billions of yen

	Q1 YTD FY2021 Results	Q1 YTD FY2022 Results	Change	
			Value	%
Revenue	131.2	159.9	28.7	21.9
Cost of sales	38.5	46.1	7.6	19.7
Gross profit	92.7	113.8	21.1	22.8
SG&A expenses	62.1	77.3	15.2	24.5
R&D expenses	22.4	24.4	2.0	8.9
Other operating income and expenses	0.1	2.5	2.4	
Operating profit	8.3	14.6	6.3	75.9
Finance income and costs	(0.3)	32.0	32.3	
Profit before taxes	8.0	46.6	38.7	485.8
Income tax expenses	7.2	18.5	11.4	
Net profit	0.8	28.1	27.3	—
Net profit attributable to owners of the parent	4.8	31.1	26.3	547.8

Appendix (Research and Development)

Main Events / Targets for FY2022 (as of July 29, 2022)

✓ Completed action / target Revisions since the announcement of May 2022 are shown in red

Psychiatry & Neurology	☐ ulotaront (SEP-363856) : ☐ Start clinical studies for two new indications ☐ Advance Phase 3 study in the U.S. and Phase 2/3 study in Japan and China for schizophrenia ☐ SEP-4199: Advance Phase 3 studies for Bipolar I depression
Oncology	✓ relugolix : (Europe) Obtain approval for prostate cancer ☐ Advance early Phase studies
Regenerative medicine / Cell therapy	☐ Allogeneic iPS cell-derived products（AMD: age-related macular degeneration) : Start clinical study ☐ Allogeneic iPS cell-derived products（Parkinson's disease) : Start clinical study in the U.S. ☐ Start construction of manufacturing plant in the U.S (for RETHYMIC® and allogeneic iPS cell-derived products)
Infectious Diseases	☐ KSP-1007（Antimicrobial resistance） : Complete Phase 1 study in the U.S. ☐ universal influenza vaccine, malaria vaccines : Promote joint research and development projects
Others	☐ relugolix : (U.S.) ☐ Obtain approval for endometriosis (Europe) ☐ Submit MAA for endometriosis
Frontier	☐ Launch products: ☐ (Japan) Neurorehabilitation device for hand/figures ☐ (U.S.) VR contents for mental health ☐ Generating evidence data for maximizing the value of the launched products: Digital device for relieving BPSD, etc. ☐ Promote the current themes and development of new themes

Appendix (Research and Development)

Product Launch Target (as of July 29, 2022)

No revisions since the announcement of May 2022



: Psychiatry & Neurology
: Oncology
: Regenerative medicine / cell therapy
: Others

* Launch schedule is based on our goal pending agreement with partners

Sumitomo Pharma

Appendix (Research and Development)

Regenerative Medicine/Cell Therapy Launched Product and Development Pipeline (as of July 29, 2022)

Revisions since the announcement of May 2022 are shown in red

Proposed indication, etc.	Partnering	Region (planned)	Cell type	status
Pediatric congenital athymia (RETHYMIC®)	Duke University	Global	Cultured thymus tissue	**Launched in March 2022 (U.S.)**
AMD (age-related macular degeneration)	Healios RIKEN	Global	Allo iPS cell-derived retinal pigment epithelium	**Preparing to start clinical study (Japan)**
Parkinson's disease (Designated as a "SAKIGAKE")	Kyoto University CiRA	Global	Allo iPS cell-derived dopamine neural progenitor	**In progress: investigator-initiated study (Phase 1 / 2 study) (Japan)** **Preparing to start clinical study (U.S.)**
Retinitis pigmentosa	RIKEN	Global	Allo iPS cell-derived photoreceptor (3D)	**In progress: clinical research**
Spinal cord injury	Keio University Osaka National Hospital	Global	Allo iPS cell-derived neural progenitor	**In progress: clinical research (Sub-Acute Phase)** **In progress: pre-clinical study (Chronic Phase)**
Kidney failure	Jikei University Bios	Japan, North America	Auto/ Allo iPS cell-based induced nephron progenitor cells (organ)	**In progress: pre-clinical study**

Aim to start clinical study in FY2022

Aim to launch in FY2024 *

* Launch schedule is based on our goal pending agreement with partners


Sumitomo Pharma
Innovation today, healthier tomorrows